Our Story
ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer. ORIC’s lead product candidate, ORIC-101, is a potent and selective small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across a variety of solid tumors. ORIC-101 is currently in two separate Phase 1b trials of ORIC-101 in combination with (1) Xtandi (enzalutamide) in metastatic prostate cancer and (2) Abraxane (nab-paclitaxel) in advanced or metastatic solid tumors. ORIC’s other product candidates include (1) ORIC-533, an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens, (2) ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and (3) ORIC-114, a brain penetrant inhibitor designed to selectively target EGFR and HER2 with high potency against exon 20 insertion mutations, being developed across multiple genetically defined cancers. Beyond these four product candidates, ORIC is also developing multiple precision medicines targeting other hallmark cancer resistance mechanisms. ORIC has offices in South San Francisco and San Diego, California. For more information, please go to www.oricpharma.com.
ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer. ORIC’s lead product candidate, ORIC-101, is a potent and selective small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across a variety of solid tumors. ORIC-101 is currently in two separate Phase 1b trials of ORIC-101 in combination with (1) Xtandi (enzalutamide) in metastatic prostate cancer and (2) Abraxane (nab-paclitaxel) in advanced or metastatic solid tumors. ORIC’s other product candidates include (1) ORIC-533, an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens, (2) ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and (3) ORIC-114, a brain penetrant inhibitor designed to selectively target EGFR and HER2 with high potency against exon 20 insertion mutations, being developed across multiple genetically defined cancers. Beyond these four product candidates, ORIC is also developing multiple precision medicines targeting other hallmark cancer resistance mechanisms. ORIC has offices in South San Francisco and San Diego, California. For more information, please go to www.oricpharma.com.
Location: United States, California, South San Francisco
Employees: 51-200
Total raised: $128M
Founded date: 2014
Investors 6
| Date | Name | Website |
| - | Foresite C... | foresiteca... |
| - | The Column... | thecolumng... |
| - | OrbiMed | orbimed.co... |
| - | Timefolio ... | timefolioc... |
| - | EcoR1 Capi... | ecor1cap.c... |
| - | Taiho Vent... | taihoventu... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 21.12.2022 | - | $25M | - |
| 21.02.2018 | Series C | $50M | - |
| 02.12.2015 | Series B | $53M | - |
Mentions in press and media 20
| Date | Title | Description |
| 19.11.2024 | The Rise of Biotech: ORIC Pharmaceuticals and OmniScience Lead the Charge | In the ever-evolving landscape of biotechnology, two companies are making waves: ORIC Pharmaceuticals and OmniScience. Both are harnessing innovation to tackle pressing health challenges. Their approaches, while distinct, share a common goa... |
| 16.11.2024 | ORIC: Working with Two Pharma Giants, Analysts See +100% Upside ORIC Pharmaceuticals is a stock analyst price targets currently signal double-bagger potential in. See what the excitement around this f... | ORIC Pharmaceuticals (NASDAQ: ORIC) is a small-cap pharma stock. It aims to make a difference with its potentially "best-in-class" treatments. The company’s shares have not had a great year, returning -4% in 2024. However, analys... |
| 11.03.2024 | ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Updates | Presented initial Phase 1b data from three clinical programs that support potential best in class profiles, with ORIC-944 and ORIC-114 prioritized for further advancement towards registrational studies Initiation of combination study of ORI... |
| 11.03.2024 | ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Updates | - |
| 06.03.2024 | ORIC Pharmaceuticals to Present at the Leerink Partners Global Biopharma Conference | - |
| 05.03.2024 | ORIC Pharmaceuticals Announces Multiple Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting | - |
| 22.01.2024 | ORIC Pharmaceuticals Announces $125 Million Private Placement Financing | Funding from new and existing investors including Viking Global Investors, Commodore Capital, Frazier Life Sciences, Venrock Healthcare Capital Partners, New Enterprise Associates (NEA), and Nextech Pro forma cash and investments expected t... |
| 22.01.2024 | ORIC Pharmaceuticals Announces $125 Million Private Placement Financing | - |
| 26.06.2023 | ORIC Pharmaceuticals Announces $85 Million Private Placement Financing | - |
| 26.06.2023 | ORIC Pharmaceuticals Announces $85 Million Private Placement Financing | /EIN News/ -- Financing led by Nextech and includes participation from EcoR1 Capital, Frazier Life Sciences, Venrock Healthcare Capital Partners, and Boxer Capital Pro forma cash and investments expected to fund current operating plan into ... |
Show more